Couldn't agree more. I'm holding onto these (even though I'm behind at present). If the patient trial finishes as expected, these shares will be as scarce as hens teeth. Top 20 hold 80% last annual report, and I only see buying from substancial holder. If someone can find a more updated top 20, I would be most grateful.after close ann
looks like the japanese commercial feasibility study is compete
and it is a go ahead with some encouraging number from a start of 0.5 milj test/ year in 2010 up to 2.9 milj in 2015 and that i only japan....
sure people have to start see beyond the start up problems/delay fermiscan had; at this stage they have already proven that the technique is more accurate, early detection is possible, all ages, no radiation,
and is new ... what means is that there is still room for optimising and tweaking
you could call me a believer but apart from the initial test/trail problems
there is a lot of upsite with this mob
if you can have the patience ....
DYOR